Covista Inc. shareholders approved the 2026 Equity Incentive Plan and elected eleven directors at the November 11, 2026 annual meeting. The board also assigned Emily Chiu and Leslie Storms to standing committees.
CVSA · Covista Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Covista reported fiscal 2027 first-quarter revenue of $511.5 million, up 10.7%, and adjusted EPS of $2.19, up 25.1%. Fiscal 2027 revenue guidance rose to $2,060,000,000 to $2,095,000,000, adjusted EPS guidance to $9 to $9.20, and CFO Bob Phelan announced his retirement.
Covista's first-quarter fiscal 2027 revenue rose 10.7%, or $49.2 million, to $511.5 million, with net income up 9.0% to $67.4 million and diluted earnings per share up 16.8% to $1.95. Consolidated operating income increased 14.7% to $98.0 million, and the company repurchased 658,088 shares at an average cost of $127.63. Cash and cash equivalents fell to $222.2 million as of September 30, 2026 from $406.3 million at June 30, 2026.
Covista Inc. reported first quarter fiscal year 2027 revenue of $511.5 million, up 10.7% year-over-year, and raised fiscal year 2027 revenue guidance to $2,060 million–$2,095 million and adjusted EPS guidance to $9.00–$9.20.
Covista Inc. issued a supplement to its proxy statement clarifying that broker non-votes do not affect the vote on Proposal No. 4, the 2026 Equity Incentive Plan, and restating voting standards for the November 11, 2026 annual meeting.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · May 7, 2026TL;DR. Covista delivered 6.8% total enrollment growth to surpass 100,000 students, with Chamberlain returning to positive enrollment growth, and raised full-year FY26 revenue and adjusted EPS guidance on stronger momentum across segments.
- + Raised full-year FY2026 revenue guidance to $1,930M–$1,945M (8–9% growth) and adjusted EPS to $7.95–$8.15 (19–22% growth).
- − Consolidated adjusted EBITDA margin of 26.3% was down 110 bps YoY (and Walden adj. EBITDA margin fell from 30.3% to 26.7%), partly due to elevated strategic growth investments planned for Q4.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $2.19 | Q1 FY 2027 | — |
|
|
|||
| Adjusted EBITDA (non-GAAP) non-GAAP | 540.91M | Twelve Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $75.8M | Q1 FY 2027 | — |
|
|
|||
| Adjusted operating income (non-GAAP) non-GAAP | 106.57M | Three Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted operating margin (non-GAAP) non-GAAP | 20.8% | Three Months Ended September 30, 2026 | — |
|
|
|||
| Free cash flow (non-GAAP) non-GAAP | 355.17M | Q1 FY27 | — |
| Repurchased shares | $84M | Q1 FY 2027 | — |
| Total enrollment | 7.6% | Q1 FY 2027 | — |
| Adjusted EBITDA (non-GAAP) - Chamberlain non-GAAP | $185.53M | Year Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) - Medical and Veterinary non-GAAP | $102.78M | Year Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) - Walden non-GAAP | $267.96M | Year Ended June 30, 2026 | — |
| Adjusted EBITDA - Home Office non-GAAP | -$34.53M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationAdjusted operating loss -$43.84M (non-GAAP)
+$658K Depreciation
+$8.66M Stock-based compensation
= Adjusted EBITDA - Home Office -$34.53M
|
|||
| Adjusted EBITDA margin non-GAAP | 25.3% | Q4 FY2026 | — |
| Adjusted EBITDA margin (non-GAAP) non-GAAP | 26.7% | Year Ended June 30, 2026 | — |
| Adjusted EBITDA margin (non-GAAP) - Chamberlain non-GAAP | 24.7% | Year Ended June 30, 2026 | — |
| Adjusted EBITDA margin (non-GAAP) - Medical and Veterinary non-GAAP | 25.8% | Year Ended June 30, 2026 | — |
| Adjusted EBITDA margin (non-GAAP) - Walden non-GAAP | 33.3% | Year Ended June 30, 2026 | — |
| Adjusted operating loss non-GAAP | -$43.84M | fiscal year 2026 filing | — |
| Average cost per share repurchased | $98.35 | fiscal year 2026 filing | — |
| Average total student enrollment at Chamberlain | 1.1% | fiscal year 2026 filing | — |
| Average total student enrollment at the medical and veterinary schools | 4.5% | fiscal year 2026 filing | — |
| Average total student enrollment at Walden | 13.2% | fiscal year 2026 filing | — |
| Chamberlain Total Students | 39,501 | Q4 FY2026 | — |
| Medical and Veterinary enrolled approximately 5,250 students on average | 5,250 | FY2026 | — |
| Medical and Veterinary Total Students | 5,120 | Q4 FY2026 | — |
| Net debt (non-GAAP) non-GAAP | $266.68M | Year Ended June 30, 2026 | — |
| Shares repurchased under share repurchase programs | 2,421,920 | fiscal year 2026 filing | — |
| Walden Total Students | 54,851 | Q4 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Education & Training Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVSA
this stock
Covista Inc.
|
$3.98B | +15.8% | +9.3% | 16.4 | 8.5% |
|
EDU
New Oriental Education & Technology Group Inc.
|
$8.22B | -3.6% | +15.5% | — | 1.6% |
|
TAL
TAL Education Group
|
$5.64B | -6.8% | +33.7% | — | 3.7% |
|
LAUR
Laureate Education, Inc.
|
$4.57B | -0.1% | +19.5% | 12.5 | 2.4% |
|
LRN
Stride, Inc.
|
$3.27B | +19.8% | +3.3% | 10.8 | 16.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 20
Covista Inc. shareholders approved the 2026 Equity Incentive Plan and elected eleven directors at the November 11, 2026 annual meeting. The board also assigned Emily Chiu and Leslie Storms to standing committees.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVSA | +0.2% | -5.6% | +1.7% | -3.6% | +15.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +4.1% | -0.1% | +5.2% | -0.3% | +8.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.